[1] C. Kearon, E. A. Akl, A. J. Comerota et al., “Antithrom-botic Therapy for Vte Disease. Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, Vol. 141, Suppl. 2, 2012, pp. e419S-e494S.
[2] K. E. Wood, “Major Pulmonary Embolism. Review of a Pathophysiologic Approach to the Golden Hour on Hemodynamically Significant Pulmonary Embolism,” Chest, Vol. 121, No. 3, 2002, pp. 877-905. doi:10.1378/chest.121.3.877
[3] J. L. Todd and V. F. Tapson, “Thrombolytic Therapy for Acute Pulmonary Embolism: A Critical Appraisal,” Chest, Vol. 135, No. 5, 2009, pp. 1321-1329. doi:10.1378/chest.08-2125
[4] L. Daniels, A. Parker, S. R. Patel, F. Grodstein and S. E. Goldhaber, “Relation of Duration of Symptoms with Response to Thrombolytic Therapy in Pulmonary Embolism,” American Journal of Cardiology, Vol. 80, No. 2, 1997, pp. 184-188. doi:10.1016/S0002-9149(97)00315-9